Akebia Therapeutics has the GF Score of 50, which implies that the company
might have
Worst future performance potential, or not enough data.
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
GF Score takes following five key aspects into consideration:
Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.
Based on research and backtesting result, GuruFocus believes Akebia Therapeutics
might have
Worst future performance potential, or not enough data.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:
GF Score
Performance Potential and All-in-One Screener Examples (1)
(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.
Akebia Therapeutics GF Score Related Terms
STU:AX9 vs TKNO, ORGO, SIGA: GF Score Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Akebia Therapeutics's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Akebia Therapeutics GF Score vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Akebia Therapeutics's GF Score distribution charts can be found below:
* The bar in red indicates where Akebia Therapeutics's GF Score falls into.
Akebia Therapeutics (STU:AX9) has a GF Score of 50 as of Jul. 01, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Akebia Therapeutics and its competitors. This is near median its historical median of 49.00. Over the past decade, Akebia Therapeutics' GF Score has ranged from 25.00 to 73.00.
Is Akebia Therapeutics' GF Score too high?
Akebia Therapeutics' current GF Score of 50 is near median its 10-year median of 49.00. Over the past 10 years, this metric has ranged from a low of 25.00 to a high of 73.00. Overall, Akebia Therapeutics has a GF Score™ of 50/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Akebia Therapeutics' GF Score compare to TKNO and ORGO?
Akebia Therapeutics' GF Score of 50 can be compared against companies in the Drug Manufacturers industry. Historically, Akebia Therapeutics' own GF Score has ranged from 25.00 to 73.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Drug Manufacturers company?
A good GF Score depends on the Drug Manufacturers industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Akebia Therapeutics and its competitors. Akebia Therapeutics's current GF Score is 50, which is near median its own 10-year median of 49.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Akebia Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Akebia Therapeutics (STU:AX9) is currently considered Modestly Undervalued. The stock's GF Value™ is €1.12, compared to a current price of €0.98 — trading 12.1% below its estimated fair value. The current GF Score is 50, which is near median its 10-year median of 49.00. Akebia Therapeutics' overall GF Score™ is 50/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Akebia Therapeutics (STU:AX9), the current GF Score is 50 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Akebia Therapeutics (STU:AX9) Overvalued in 2026?
Based on GuruFocus' analysis, Akebia Therapeutics stock appears to be undervalued.
The current stock price of €0.98 is trading 12.1% below its estimated GF Value™ of €1.12.
GuruFocus considers Akebia Therapeutics to be Modestly Undervalued.
Key valuation signals for STU:AX9:
GF Score: 50 (near median its 10-year median of 49.00)
GF Value™: €1.12 vs. price of €0.98 (12.1% below fair value)
No single metric tells the full story. See the STU:AX9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.
50GF Score
Get the complete analysis for STU:AX9
GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:AX9 has been successfully added to your 